286
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Efficacy and safety of endoscopic submucosal dissection for gastrointestinal neuroendocrine tumors: a 10-year data analysis of Northern China

ORCID Icon, ORCID Icon, , , ORCID Icon, , , , , , , & show all
Pages 384-389 | Received 12 Jan 2019, Accepted 22 Feb 2019, Published online: 30 Apr 2019

References

  • Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18.
  • Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.
  • Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589–597.
  • Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.
  • Delle Fave G, O'Toole D, Sundin A, et al. ENETS Consensus Guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:119–124.
  • Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med. 1995;46:395–411.
  • Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959.
  • Bertani E, Ravizza D, Milione M, et al. Neuroendocrine neoplasms of rectum: a management update. Cancer Treat Rev. 2018;66:45–55.
  • Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6–32.
  • Kulke MH, Shah MH, Benson AB, 3rd, et al. Neuroendocrine tumors, version 1. 2015. J Natl Compr Canc Netw. 2015;13:78–108.
  • Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–577.
  • Norton JA, Kim T, Kim J, et al. SSAT state-of-the-art conference: current surgical management of gastric tumors. J Gastrointest Surg. 2018;22:32–42.
  • Sato Y. Endoscopic diagnosis and management of type I neuroendocrine tumors. World J Gastrointest Endosc. 2015;7:346–353.
  • Sato Y, Imamura H, Kaizaki Y, et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc. 2014;26:377–384.
  • Uygun A, Kadayifci A, Polat Z, et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. J Surg Oncol. 2014;109:71–74.
  • Kim HH, Kim GH, Kim JH, et al. The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol Res Pract. 2014;253860.
  • Li QL, Zhang YQ, Chen WF, et al. Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World J Gastroenterol. 2012;18:5799–5806.
  • Ravizza D, Fiori G, Trovato C, et al. Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis. 2007;39:537–543.
  • O'Shea T, Druce M. When should genetic testing be performed in patients with neuroendocrine tumours?. Rev Endocr Metab Disord. 2017;18:499–515.
  • Bornstein-Quevedo L, Gamboa-Domínguez A. Carcinoid tumors of the duodenum and ampulla of vater: a clinicomorphologic, immunohistochemical, and cell kinetic comparison. Hum Pathol. 2001;32:1252–1256.
  • Sato Y, Hashimoto S, Mizuno K, et al. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22:6817–6828.
  • Kim GH, Kim JI, Jeon SW, et al. Endoscopic resection for duodenal carcinoid tumors: a multicenter, retrospective study. J Gastroenterol Hepatol. 2014;29:318–324.
  • Singh S, Asa SL, Dey C, et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32–45.
  • Spychalski M, Koptas W, Zelga P, et al. Role of endoscopic submucosal dissection in treatment of rectal gastroenteropancreatic neuroendocrine neoplasms. Prz Gastroenterol. 2017;12:17–21.
  • Zhang HP, Wu W, Yang S, et al. Endoscopic treatments for rectal neuroendocrine tumors smaller than 16 mm: a meta-analysis. Scand J Gastroenterol. 2016;51:1345–1353.
  • Basuroy R, Haji A, Ramage JK, et al. Review article: the investigation and management of rectal neuroendocrine tumours. Aliment Pharmacol Ther. 2016;44:332–345.
  • He L, Deng T, Luo H. Efficacy and safety of endoscopic resection therapies for rectal carcinoid tumors: a meta-analysis. Yonsei Med J. 2015;56:72–81.
  • Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–762.
  • Caplin M, Sundin A, Nillson O, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95:88–97.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.